AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca has initiated a Phase III clinical study titled ‘A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event.’ The study aims to evaluate the efficacy and safety of AZD0780 in reducing LDL-C levels in adults with clinical ASCVD or at risk for a first ASCVD event.
The intervention being tested is AZD0780, a small molecule drug intended to lower LDL-C levels in the blood. It is administered orally once daily and is compared against a placebo.
This interventional study is designed as a randomized, double-blind, placebo-controlled, parallel-group trial. It involves masking of participants, care providers, and investigators to ensure unbiased results, with the primary purpose being treatment.
The study began on May 28, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on July 22, 2025, indicating ongoing recruitment.
The market implications of this study are significant for AstraZeneca, as positive results could enhance investor confidence and potentially boost stock performance. In a competitive pharmaceutical landscape, advancements in cardiovascular treatments are crucial, and this study positions AstraZeneca as a key player in this domain.
The study is currently ongoing, and further details can be accessed on the ClinicalTrials portal.